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We transfected naked HGF plasmid DNA into cultured cardiomyocytes using a sonoporation method consisting of ultrasound-
triggered bubble liposome destruction. We examined the effects on transfection efficiency of three concentrations of bubble
liposome (1 × 106, 1 × 107, 1 × 108/mL), three concentrations of HGF DNA (60, 120, 180 μg/mL), two insonification times (30,
60 sec), and three incubation times (15, 60, 120 min). We found that low concentrations of bubble liposome and low concentrations
of DNA provided the largest amount of the HGF protein expression by the sonoporated cardiomyocytes. Variation of insonification
and incubation times did not affect the amount of product. Following insonification, cardiomyocytes showed cellular injury, as
determined by a dye exclusion test. The extent of injury was most severe with the highest concentration of bubble liposome. In
conclusion, there are some trade-offs between gene transfection efficiency and cellular injury using ultrasound-triggered bubble
liposome destruction as a method for gene transfection.
1. Introduction
Ultrasound-triggered bubble liposome destruction (sono-
poration) has been proposed as a safe nonviral means of
gene therapy that can target many different cells or tissues.
In the field of cardiovascular medicine, this method may
have significant potential for the introduction of therapeutic
genes directly into vascular cells or cardiomyocytes [1, 2].
Sonoporation can only be clinically effective if the dose-
effect relationship between the amount of bubble liposome
and transfection efficiency is first established. However, few
reports have already examined this dose-effect relationship
and the safety of the procedure [3].
Transfection efficiency in sonoporation depends on
various conditions including type of microbubble, mode of
ultrasound, frequency of ultrasound, intensity of acoustic
pressure, concentration of microbubble, dose of DNA,
duration of insonification, incubation time of cell with
DNA, repeat count of insonification, type of targeted cell,
and other physicochemical conditions like temperature and
carbon dioxide concentration, [3]. Greenleaf et al. reported
that ultrasound acoustic pressure, DNA concentration, and
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repeat count of insonification correlated with transfection
rate [4]. Teupe et al. demonstrated that duration of insoni-
fication did not affect transfection rate [5]. Then, Chen et
al. showed that transfection rate reached plateau when DNA
concentration was increased [6].
Greenleaf et al. also showed that transfection rate peaked
and fell off according to the change in liposome concen-
tration [4]. They thought it might be derived from cellular
toxicity of large amount of liposome. Li et al. reported
that cell viability decreased along with the increase in
microbubble concentration [1]. Guo et al. demonstrated that
cell viability decreased with the increase in duration of
insonification [7]. Suzuki et al. and Li et al. showed that cell
viability decreased with the increase in ultrasound acoustic
pressure [8, 9].
On the basis of those previous findings, we planned to
examine the effects of amount of plasmid DNA, liposome
concentration, duration of insonification, repeat count of
insonification, and time of incubation with liposome, cell,
and DNA on transfection rate, which was measured by means
of HGF protein release into culture medium.
2. Materials and Methods
2.1. Cell Culture. Primary cultures of neonatal ventricular
myocytes were prepared as described previously [10]. Briefly,
apical halves of cardiac ventricles from 1-day-old Wistar
rats were separated, minced, and dispersed with 0.1% col-
lagenase type II (Worthington Biochemical Corp., Freehold,
NJ). Myocytes were segregated from nonmyocytes using a
discontinuous Percoll gradient (Sigma Chemical Co., Inc., St.
Louis, MO). After centrifugation, the upper layer consisted of
a mixed population of nonmyocyte cell types and the lower
layer consisted almost exclusively of cardiac myocytes. After
the myocytes had been incubated twice on uncoated 10-
cm culture dishes for 30 minutes to remove any remaining
nonmyocytes, the nonattached viable cells were plated on
gelatin-coated 24-well culture plates or 10-cm culture dishes
and then cultured in DMEM (Life Technologies, Grand
Island, NY) supplemented with 10% FCS (Life Technologies,
Grand Island, NY). After 24-hour incubation in DMEM
with FCS, the culture medium was changed to serum-free
DMEM, and all experiments were performed 24 hours later.
This purification procedure has well been established [11,
12], and >95% of the cells obtained by this method were
cardiomyocytes.
2.2. Plasmid DNA. Preparation of rat hepatocyte growth fac-
tor (HGF) expression plasmid DNA was described previously
[13]. Briefly, rat HGF cDNA cloned by polymerase chain
reaction was inserted into the unique Xho I site between
the cytomegalovirus immediate-early enhancer-chicken β-
actin hybrid promoter and rabbit β-globin poly A site
of the pCAGGS expression plasmid [14]. The resulting
plasmid, pCAGGS-HGF, was grown in Escherichia coli
DH5α (Figure 1(a)). The plasmid was purified with a
QUIAGEN plasmid DNA kit and dissolved in TE buffer. The
purified plasmid DNA was stored at −20◦C and diluted to
the required concentration with distilled water immediately
before use.
2.3. Bubble Liposome. Liposome microbubble, SHU 508A,
consists of palmitic acid and galactose and provides
echogenic micron-sized air bubbles when suspended in
water. The diameter of bubbles ranges from 2 to 8 μm, and
97% are smaller than 6 μm [15]. These air bubbles are
stabilized by palmitic acid, which forms a molecular film
that lowers the surface tension of the aqueous vehicle.
The SHU 508A bubbles are nontoxic, have a neutral pH,
are biodegradable, and are made from a physiologically
occurring substance. The physiochemical properties of SHU
508A bubbles are typical of a saccharide solution [15].
2.4. Experiment on Ultrasound Mode. Before performing
the experiments for dose-effect relationships using liposome
sonoporation, we needed to determine the most appropri-
ate ultrasound mode for the sonoporation procedure for
efficient transfection. We tested four modes of ultrasound:
pulsed wave Doppler, color flow Doppler, continuous wave
Doppler, and harmonic power Doppler, which are available
with standard echocardiographic machinery in a clinical lab-
oratory. We performed a simple transfection experiment at
the same acoustic pressure of 0.5 W/cm2 for each ultrasound
mode, using a single condition with 60 μg HGF plasmid
DNA, 1 × 107 particles/mL of SHU 508A liposome, 30 sec
insonification, 15 min of DNA incubation, and 3 repetitions
of insonification.
Rat neonatal cardiomyocytes were inoculated and grown
to confluence in DMEM+10% FCS. After confluence had
been reached in a 35 mm Petri dish, the medium was changed
to fresh defined serum-free medium. Plasmid DNA was
diluted with distilled water immediately before the transfec-
tion. Each experiment was performed on 20 dishes. Cells on
each dish were treated with ultrasound (Figure 1(b)). Pulsed
wave Doppler, color flow Doppler, and continuous wave
Doppler were insonified from PSK-25AT acoustic transducer
with Toshiba SSA-380A (Toshiba Medical Systems), and
harmonic power Doppler was insonified from S3 transducer
with Sonos 5500 (Phillips Medical Systems). The exper-
imental results are shown in Figure 2. Continuous-wave
Doppler ultrasound was the most efficacious and was used
for subsequent experiments.
2.5. Experiments for Dose-Effect Relations. The medium
in 35 mm Petri dishes containing the cardiomyocytes
was changed to fresh defined serum-free medium from
DMEM+10% FCS. Rat HGF plasmid DNA was diluted with
distilled water, and a volume corresponding to 60, 120, or
180 μg was added to each of the 20 Petri dishes per DNA dose.
Cells on each dish were then treated with continuous-wave
Doppler ultrasound (frequency of 2.5 MHz and acoustic
intensity of 0.5 W/cm2 from a PSK-25AT acoustic transducer
with Toshiba SSA-380A Ultrasound system) with SHU 508A
liposome (1 × 107 particles/mL) for acoustic exposure time
of 30 or 60 seconds at room temperature (Figure 1(b)).
In a separate series of experiments, we tested four liposome
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Figure 1: (a) Structure of the expression plasmid pCAGGS-HGF. The expression cassette of pCAGGS-HGF contains chicken β-actin
promoter, rat HGF, and rabbit β-globin poly A. (b) Experimental setup. The transducer was attached to the bottom of the dish.
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Figure 2: Comparison of four modes of ultrasound for sono-
poration. Cells treated with continuous-wave Doppler ultrasound
yielded the largest amount of HGF protein indicating this to be the
most effective ultrasound mode. CFD: color flow Doppler; PWD:
pulsed wave Doppler; CWD: continuous wave Doppler; Harmonic:
harmonic power Doppler. ∗P < .05 versus DNA alone; ∗∗P < .05
versus CFD; ∗∗∗P < .05 versus PWD; †P < .05 versus Harmonic.
concentrations (0, 1 × 106, 1 × 107 or 1 × 108 particles/mL),
three insonification repetitions (1 insonification only, 3 or 5
insonifications for 30 seconds), and three DNA incubation
times (15, 60 or 120 min). After the incubation, the culture
medium was changed to normal DMEM+10% FCS and
the cells were cultured for 72 hours. In a separate set
of experiments, we examined the effect of culture period
on the amount of DNA product that is HGF protein by
discontinuing culture at 24, 48, and 72 hours and measuring
the amount of rat HGF protein in the medium. The total
amount of protein content in the cultured cells was measured
and used to correct the HGF level in each dish. We measured
rat HGF protein using an EIA kit (Institute of Immunology
Co., Ltd., Tokyo, Japan) [13] and protein content of cultured
cells using a Modified Lowry Protein Assay Kit (Pierce
Biotechnology, Rockford).
2.6. Viability of Cultured Cells. To determine the safety
of sonoporation, in a separate experiment, cultured cells
were exposed to 0.1% trypan blue for 5 min just after
ultrasound insonification. This allowed assessment of sar-
colemmal membrane damage and was performed for each
concentration of liposome, each insonification time, and
each number of repetitions of insonification. The number
of stained and unstained cells in the dishes was counted
and used to calculate the percentage of intact cells [16].
The degree of cellular injury caused by sonoporation was
determined by examining the insonified cells by scanning
electron microscopy (Hitachi S-4800). Immediately after
ultrasound insonification in the presence of liposome, the
cardiomyocytes were fixed with phosphate-buffered 2.5%
glutaraldehyde for 4 hours, followed by postfixation with 1%
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osmium tetroxide for 1 hour, and then were conventionally
prepared for scanning electron microscopy.
2.7. Statistical Analysis. Data were expressed as the mean ±
SEM. Comparisons of parameters from experimental groups
were performed with unpaired t tests and resulting P-
values were corrected according to the Bonferroni method.
In analyses, P < .05 was considered to indicate statistical
significance.
3. Results
3.1. Effect of Culture Period on HGF Protein Production by
Sonoporated Cardiomyocytes. The concentration of HGF
protein in the culture medium increased as the culture period
after ultrasonic transfection was extended. The transfection
consisted of three 30-sec insonifications a 15-min incubation
with HGF DNA (60 μg) and liposome (1 × 107 particle/mL)
(Figure 3(a)). After 72 hours of culture, HGF protein concen-
tration in the culture medium was measured and corrected
using the protein content of the cultured cells.
3.2. Effect of the Amount of Plasmid DNA onHGF Protein Pro-
duction by Sonoporated Cardiomyocytes. HGF protein con-
centration in the culture medium was 0.54±0.049 ng/mL/mg
and was highest when 60 μg of DNA was administered with
a liposome concentration of 1 × 107 particles/mL, a15-min
incubation, and three 30-sec insonification. Although the
nominal mean values of HGF protein after transfection of
120 and 180 μg DNA were lower than those after transfection
of 60 μg, the differences were not statistically significant
(Figure 3(b)).
3.3. Effect of Incubation Period with Plasmid DNA and Lipo-
some on HGF Protein Production by Sonoporated Cardiomy-
ocytes. HGF protein concentration in the culture medium
was 0.56 ± 0.053 ng/mL/mg and was highest when the
incubation time was 15 min with a liposome concentration
of 1 × 107 particles/mL, 60 μg DNA, and three 30-sec
insonification. Although the mean values of HGF protein
after transfection for 60 and 120 min were lower than those
after 15 min incubation, the differences were not statistically
significant (Figure 3(c)).
3.4. Effect of Insonification Time on HGF Protein Production
by Sonoporated Cardiomyocytes. HGF protein concentration
in the culture medium was 0.59 ± 0.052 ng/mL/mg and was
highest when the insonification period was 30 sec with 60 μg
DNA, a liposome concentration of 1 × 107 particles/mL,
and 15-min incubation. There was no significant difference
in HGF production in cells insonified for 30 and 60 min
(Figure 3(d)).
3.5. Effect of Liposome Concentration on HGF Protein Produc-
tion by Sonoporated Cardiomyocytes. HGF protein concen-
tration in the culture medium was 0.53 ± 0.053 ng/mL/mg
and was nominally highest when the liposome concentration
was 1 × 107 particles/mL and insonification consisted of
three 30-sec ultrasound exposures, though it was statistically
similar to that obtained with 1×106 particles/mL. At a higher
liposome concentration of 1×108 particles/mL, HGF protein
concentration decreased (Figure 3(e)).
3.6. Effect of Repetition of Insonification on HGF Protein Pro-
duction by Sonoporated Cardiomyocytes. HGF protein con-
centration in the culture medium was 0.54 ± 0.053 ng/mL/
mg and was highest when three 30-sec insonifications were
given, with a liposome concentration of 1× 107 particles/mL
and 60 mg DNA. This protein production was statisti-
cally higher than in cells given one or five insonifications
(Figure 3(f)).
3.7. Effect of Insonification Time on Cell Viability. The per-
centage of dead cells was 14.7 ± 0.9% and was higher in the
cells given five 30-sec insonifications at a liposome concen-
tration of 1 × 107 particles/mL (Figure 4(a)). There was no
statistical difference between 30- and 60-sec insonification.
3.8. Effect of Liposome Concentration on Cell Viability. The
percentage of dead cells increased with increasing concen-
trations of liposome (Figure 4(b)). The dead cell count was
24.8 ± 2.9% and was highest when the liposome concentra-
tion was 1×108 particles/mL and three 30-sec insonifications
were used.
3.9. Effect of Number of Insonification Repetitions on Cell Via-
bility. The percentage of dead cells increased as the number
of insonification repetitions increased (Figure 4(c)). The
dead cell count was 14.7 ± 0.9% and was highest when
five repetitions of the insonification step were given, with
a liposome concentration of 1× 107 particles/mL.
3.10. Scanning Electron Microscopy Observations of Sonopo-
rated Cardiomyocytes. No particular changes were evident
on the surfaces of untreated control cultured cardiomyocytes
when viewed with the scanning electron microscope at low
and high magnification (Figures 5(a) and 5(b)). After sono-
poration with a low concentration of liposome (Figure 5(c))
and with a high concentration of liposome (Figure 5(d)),
microdimples or pores were observed on the surfaces of the
cultured cardiomyocytes.
4. Discussion
Considerable efforts have been made to develop methods
that will allow effective and safe introduction of vectors into
cells for gene therapy. However, we still need a breakthrough
in the form of a novel vector that will transform cells at
high efficiency and with low risk of adverse effects. This is
especially true in cardiovascular medicine, where malignant
cellular transformation is rare [17]. One of the promising
candidates for safe and efficacious gene transfection is a
naked plasmid vector that has been modified to have high
affinity for cardiovascular tissues but which has no built-
in viral components [17, 18]. We have developed a method
for electroporation of a cytokine gene for treatment of
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Figure 3: (a) Effect of culture period after transfection of HGF DNA on HGF protein production using 60 μg of DNA and 1×107 particles/mL
liposome with three 30-sec insonifications and 15-min incubation with DNA. Baseline was the concentration of rat HGF protein in the
culture medium around rat cardiomyocytes without any intervention at the beginning of cell culture. ∗P < .05 versus baseline; ∗∗P <
.05 versus 24 hours after the onset of culture; ∗∗∗P < .05 versus 48 hours after the onset of culture. (b) Effect of amount of plasmid
DNA on HGF protein production using 1× 107 particles/mL liposome with three 30-sec insonifications and 15-min incubation with DNA.
“DNA alone” indicates the concentration of rat HGF protein in the culture medium of cardiomyocytes treated with 60 μg DNA without
insonification. ∗P < .05 versus DNA alone. (c) Effect of incubation period of cardiomyocytes with plasmid DNA and liposome on HGF
protein production using 60 μg of DNA and 1 × 107 particles/mL liposome with three 30-sec insonifications. ∗P < .05 versus DNA alone.
(d) Effect of insonification time on protein production using 60 μg of DNA, 1 × 107 particles/mL liposome, and 15-min incubation with
DNA, and three 30- or 60-sec insonifications. ∗P < .05 versus DNA alone. (e) Effect of liposome concentration on HGF protein production
using 60 μg of DNA with three 30-sec insonifications and 15-min incubation with DNA. ∗P < .05 versus DNA alone; ∗∗P < .05 versus 0
particles/mL; ∗∗∗P < .05 versus 1×108 particles/mL. (f) Effect of repetition of insonification on HGF protein production using 6 μg of DNA
and 1 × 107 particles/mL liposome with 15-min incubation with DNA. ∗P < .05 versus DNA alone; ∗∗P < .05 versus 1 time; ∗∗∗P < .05
versus 5 times.
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Figure 4: (a) Effect of insonification time on cell viability using 60 μg of DNA, 1× 107 particles/mL liposome, and 15-min incubation with
DNA, and three 30- or 60-sec insonifications. “US alone” represents the percentage of dead cells immediately after three 30-sec insonifications
in the absence of liposome and DNA. ∗P < .05 versus baseline. (b) Effect of liposome concentration on cell viability using 60 μg of DNA and
three 30-sec insonifications and 15-min incubation with DNA. ∗P < .05 versus baseline; ∗∗P < .05 versus 1 × 106 particles/mL; ∗∗∗P < .05
versus 1×108 particles/mL. (c) Effect of repetitions of insonification on cell viability using 60 μg of DNA, 1×107 particles/mL liposome, and
15-min incubation with DNA. ∗P < .05 versus baseline; ∗∗P < .05 versus 30 sec × 1.
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Figure 5: (a) and (b) Scanning electron microscopic images of intact cell surfaces of cultured cardiomyocytes. Scale dots are indicated on
the images. (c) Image of a cell surface immediately after sonoporation using 1 × 106 particles/mL liposome. (d) Image of a cell surface
immediately after sonoporation using 1× 108 particles/mL liposome.
cardiomyopathy [13]. However, using electric shock for
transfection is not clinically practical. For this reason, we are
pursuing the present sonoporation method as a protocol for
gene transfection.
The HGF protein used in the present study is found
in a wide variety of cell types and has multiple biological
properties, including mitogenic, motogenic, morphogenic
and antiapoptotic activities [19]. Several lines of evidence
indicate that this molecule has potential for therapeutic use
for treatment of heart failure, myocardial infarction, angina,
and hypertension [20–22]. HGF may also have enormous
therapeutic potential for hepatic and renal disorders, in
addition to cardiovascular diseases [23–26].
In the present study, we showed variations in amount of
HGF plasmid DNA, liposome concentration, the duration of
insonification, and incubation time of the cardiomyocytes
with liposome and DNA, and their dose relationships with
the final amount of HGF protein released from the cultured
neonatal cardiomyocytes. We found that specific amounts
of liposome and repetitions of insonification were needed
for effective protein production from cardiomyocytes. How-
ever, high concentrations of bubble liposome and large
numbers of repeat insonifications resulted in decreased cell
viability.
Plasma membrane sonoporation induced by ultrasound
and subsequent self-sealing has been reported in previous
investigations [27–29]. However, the exact mechanism by
which membrane sonoporation causes substance incorpora-
tion into the cell is not yet understood. Some investigators
speculate that the membrane poration results in both trans-
fection efficiency and cellular damage. In the present study,
scanning microscopy images revealed some microdimples
or pores on the cell surface after sonoporation, which did
not exist on the surface of control cardiomyocytes. The
numbers of dimples or pores tended to increase with higher
concentrations of liposome. Thus, we speculate that these
dimples or pores on the cell surface might be related to
transfection efficiency and might be evidence of cellular
injury by sonoporation. Previous studies of sonoporation of
vascular walls revealed that microbubble destruction would
cause rupture of microvessels and extravasation [30–33],
which would cancel out some benefits of sonoporation.
Thus, the poration and self-sealing mechanism needs to be
fully investigated and optimized.
A sonoporation technique targeting the cardiovascular
system has now been developed for gene transfection to
myocardium, limb skeletal muscle, and arteries [34–37].
For a variety of target tissues, a number of microbubbles,
including liposomes, and a range of ultrasound modes have
been developed. The optimal combination of the type of
microbubble, ultrasound mode, and target tissue still needs
to be resolved [38–40]. However, the principal types of
ultrasound used for sonoporation have included pulsed wave
Doppler or continuous wave Doppler with acoustic pressure
ranging 0.5–5 W/cm2 [34–37]. In the present study, we found
that continuous wave Doppler at a standard frequency for
clinical use, that is, 2.5 MHz and the usual acoustic pressure
of 0.5 W/cm2, was most effective with our cardiomyocytes.
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The reason we used one of the standard ultrasound modes
with standard settings for clinical use is that we would like to
use our sonoporation system eventually in a clinical setting.
The present study has several limitations. To avoid the
complexity of numerous combinations of experimental con-
ditions, such as amount of DNA, concentration of liposome,
duration of insonification, repeat count of insonification,
length of incubation time, and culture period after gene
transfection, we only used several practical combinations for
an in vitro experiment for cultured cardiomyocytes. Thus, we
might have missed other multimodal aspects of dose-effect
relationships among these conditions.
5. Conclusion
HGF DNA was successfully transferred to cultured car-
diomyocytes using sonoporation with a defined liposome
concentration and a mode of insonification. A number of
trade-offs between transfection efficiency and cellular injury
have to be balanced to optimize this sonoporation method.
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